June 13–14, 2019
Boston Marriott Long Wharf,
Rare Disease Innovation and Partnering Summit
Connect with Key Stakeholders and Propel Curative Progress, Orphan Product Success and Patient Advocacy
KEYNOTE TOPICS INCLUDE:
Patient and Caregiver Perspectives –
Explore New Developments in Cures, Community, Collaboration and the Care Continuum for Patients and Caregivers
Science Luminaries –
Advancements in Gene Therapy that Are Tearing Down Barriers to Discovery in Rare Disease
Regulatory and Policy Update Address –
Legislative Updates and New Initiatives within the FDA’s Orphan Drug Program
Focus on Funding –
The Impact of Disruptive Investors, Drivers of Value and Funding Models for Success
Technology Spotlight –
Artificial Intelligence (AI) and Advanced Data Analytics — Reshaping Complex Diagnostics and Decision-Making in Rare Disease Drug Development
2019 Program Advisory Board
I thought this was one of the best conferences I’ve attended over the years. The focus was very practical and each speaker shared real world examples instead of theory. It was well organized and the passion each participant has for helping people with rare disease was very evident.
Regulatory Affairs, North America
The Rare Disease Innovation Summit provided the opportunity for cross communication between industry, nonprofits and vendors who bridge the gap between the two. From presentations to panels, every attendee walked away with new information and resources to help improve the quality of life for the rare disease community. Thank you for making this possible CBI!
President & CEO
Tuberous Sclerosis Alliance
The inaugural Rare Disease Innovation Conference brought together multidisciplinary stakeholders to discuss important issues challenging the rare disease ecosystem. The contributions by the audience accelerated thinking how to address and eventually resolve key access related issues impacting people in desperate need of therapeutic options.
Senior Vice President, Global Business Operations and External Affairs
Most amazing were the voices from the patient community who are driving drug discovery and access. What some doing for a few benefits us all in this rare space. CBI’s Summit was a prime example of how the patients are critical to informing the research and development dialogue but also vice versa. We need to know the innovations planned and in progress.
President & CEO
Canadian Organization of Rare Disorders
The rare Innovation summit is an intimate engaging meeting facilitating discussion amongst speakers and attendees – nice mix of industry and patient groups especially stakeholders I haven’t met before at other meetings.
Global Medical Lead, Patient Engagement, Rare Diseases